Universitatsklinik Tuebingen
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Degen, Loreen
MK-4002-001, NCT04184050 / 2019-004793-26: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002

Checkmark Data from trial for multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for multiple myeloma at ASH 2022
Checkmark Data from trial for r/r multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for r/r multiple myeloma at ASH 2022
Checkmark Data from trial for multiple myeloma at ASH 2021
More
Active, not recruiting
1
100
Europe, US
MK-4002, HPN217
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
06/25
11/25
Besemer, Britta
DREAMM8, NCT04484623 / 2018-004354-21: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

Jan 2024 - Dec 2024: Market entry for 2L multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in Japan for 2L+ multiple myeloma (based on DREAMM-8 trial)
Jan 2024 - Dec 2024: Regulatory approval in EU for 2L+ multiple myeloma (based on DREAMM-7 trial)
Jan 2024 - Dec 2024: Regulatory approval in US for 2L+ multiple myeloma (based on DREAMM-7 trial)
Hourglass Jul 2024 - Dec 2024 : Acceptance of regulatory submission in EU for 2L+ multiple myeloma (based on DREAMM-8 trial)
More
Recruiting
3
357
Europe, Japan, US, RoW
Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib
GlaxoSmithKline
Multiple Myeloma
01/24
05/29
AlloRelapseMM, NCT05675319: Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

Recruiting
3
482
Europe
Allogeneic Stem Cells, carfilzomib/lenalidomide/dexamethasone (KRD), elotuzumab/lenalidomide/dexamethasone (ERD), daratumumab/bortezomib/dexamethasone (DVD), daratumumab/lenalidomide/dexamethasone (DRD), ixazomib/lenalidomide/dexamethasone (IRD), pomalidomide/bortezomib/dexamethasone (PVD), carfilzomib/daratumumab/dexamethasone (KDD), Autologous Stem Cells, daratumumab/pomalidomide/dexamethasone (DPD), isatuximab/carfilzomib/dexamethasone (Isa-KD), selinexor/bortezomib/dexamethasone (SVD)
Universitätsklinikum Hamburg-Eppendorf, Gemeinsamer Bundesausschuss (G-BA), Staburo GmbH
Multiple Myeloma
03/28
03/33
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
MK-4002-001, NCT04184050 / 2019-004793-26: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002

Checkmark Data from trial for multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for multiple myeloma at ASH 2022
Checkmark Data from trial for r/r multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for r/r multiple myeloma at ASH 2022
Checkmark Data from trial for multiple myeloma at ASH 2021
More
Active, not recruiting
1
100
Europe, US
MK-4002, HPN217
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
06/25
11/25
DREAMM 9, NCT04091126 / 2019-003047-30: Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Checkmark From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: From DREAMM-9 trial for 1L transplant ineligible multiple myeloma at ASH 2021
Recruiting
1
144
Europe, Canada, US, RoW
Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
GlaxoSmithKline
Multiple Myeloma
11/24
06/25

Download Options